Sectors & IndustriesHealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2025)
Top diagnostic & research stocks in 2025 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research
C
Diagnostics & Research is Zen Rated C and is the 72nd ranked industry out of 145 stock market industries
Learn how the Zen Ratings work
Ticker
Company
Market Cap
Dividend Yield
Payout Ratio
Last Dividend
Annual Dividend
Dividend Percentile
Dividend Dropped Count (L10Y)
Ex-dividend Date
Div. Payment Date
FONR
FONAR CORP
$102.74MN/A0.00%N/AN/AN/AN/A
SHC
SOTERA HEALTH CO
$4.43BN/A0.00%N/AN/AN/AN/A
IDXX
IDEXX LABORATORIES INC
$51.44BN/A0.00%N/AN/AN/AN/A
CRL
CHARLES RIVER LABORATORIES INTERNATIONAL INC
$8.07BN/A0.00%N/AN/AN/AN/A
LH
LABCORP HOLDINGS INC
$23.16B1.03%31.50%$0.7200$2.8824%02025-09-11
QGEN
QIAGEN NV
$10.35BN/A0.00%$1.2800N/AN/A0
DHR
DANAHER CORP
$143.36B0.45%24.90%$0.3200$0.918%2
EXAS
EXACT SCIENCES CORP
$10.19BN/A0.00%N/AN/AN/AN/A
A
AGILENT TECHNOLOGIES INC
$36.50B0.57%22.90%$0.2480$0.7312%0
TMO
THERMO FISHER SCIENTIFIC INC
$186.01B0.33%9.50%$0.4300$1.645%02025-09-152025-10-15
IQV
IQVIA HOLDINGS INC
$31.91BN/A0.00%N/AN/AN/AN/A
DGX
QUEST DIAGNOSTICS INC
$20.52B1.28%36.60%$0.8000$2.3530%02025-10-032025-10-20
MEDP
MEDPACE HOLDINGS INC
$13.68BN/A0.00%N/AN/AN/AN/A
ILMN
ILLUMINA INC
$15.21BN/A0.00%N/AN/AN/AN/A
WAT
WATERS CORP
$18.23BN/A0.00%N/AN/AN/AN/A
MTD
METTLER TOLEDO INTERNATIONAL INC
$26.90BN/A0.00%N/AN/AN/AN/A
FLGT
FULGENT GENETICS INC
$671.87MN/A0.00%N/AN/AN/AN/A
TWST
TWIST BIOSCIENCE CORP
$1.55BN/A0.00%N/AN/AN/AN/A
RDNT
RADNET INC
$5.49BN/A0.00%N/AN/AN/AN/A
RVTY
REVVITY INC
$10.06B0.24%11.90%$0.0700$0.213%02025-10-172025-11-07
MYGN
MYRIAD GENETICS INC
$615.02MN/A0.00%N/AN/AN/AN/A
XGN
EXAGEN INC
$212.78MN/A0.00%N/AN/AN/AN/A
ACRS
ACLARIS THERAPEUTICS INC
$227.39MN/A0.00%N/AN/AN/AN/A
NEO
NEOGENOMICS INC
$1.03BN/A0.00%N/AN/AN/AN/A
PRE
PRENETICS GLOBAL LTD
$105.19MN/A0.00%N/AN/AN/AN/A
NTRA
NATERA INC
$22.94BN/A0.00%N/AN/AN/AN/A
GRAL
GRAIL INC
$1.33BN/A0.00%N/AN/AN/AN/A
MDXH
MDXHEALTH SA
$17.47MN/A0.00%N/AN/AN/AN/A
GH
GUARDANT HEALTH INC
$7.50BN/A0.00%N/AN/AN/AN/A
ICLR
ICON PLC
$13.60BN/A0.00%N/AN/AN/AN/A
CSTL
CASTLE BIOSCIENCES INC
$683.44MN/A0.00%N/AN/AN/AN/A
LAB
STANDARD BIOTOOLS INC
$496.59MN/A0.00%N/AN/AN/AN/A
STIM
NEURONETICS INC
$213.58MN/A0.00%N/AN/AN/AN/A
NOTV
INOTIV INC
$56.34MN/A0.00%N/AN/AN/AN/A
CAI
CARIS LIFE SCIENCES INC
$9.80BN/AN/AN/AN/AN/AN/A
SERA
SERA PROGNOSTICS INC
$127.13MN/A0.00%N/AN/AN/AN/A
PSNL
PERSONALIS INC
$464.67MN/A0.00%N/AN/AN/AN/A
CDNA
CAREDX INC
$735.60MN/A0.00%N/AN/AN/AN/A
ISPC
ISPECIMEN INC
$4.73MN/A0.00%N/AN/AN/AN/A
NEOG
NEOGEN CORP
$1.25BN/A0.00%N/AN/AN/AN/A
OPK
OPKO HEALTH INC
$1.07BN/A0.00%N/AN/AN/AN/A
APDN
APPLIED DNA SCIENCES INC
$3.09MN/A0.00%N/AN/AN/AN/A
VNRX
VOLITIONRX LTD
$64.56MN/A0.00%N/AN/AN/AN/A
TRIB
TRINITY BIOTECH PLC
$20.83MN/A0.00%N/AN/AN/AN/A
BNR
BURNING ROCK BIOTECH LTD
$89.32MN/A0.00%N/AN/AN/AN/A
ADVB
ADVANCED BIOMED INC
$9.05MN/AN/AN/AN/AN/AN/A
PRPO
PRECIPIO INC
$28.73MN/A0.00%N/AN/AN/AN/A
DRIO
DARIOHEALTH CORP
$21.84MN/A0.00%N/AN/AN/AN/A
PRPH
PROPHASE LABS INC
$14.75MN/A0.00%$0.3000N/AN/A0
XWEL
XWELL INC
$6.27MN/A0.00%N/AN/AN/AN/A
NDRA
ENDRA LIFE SCIENCES INC
$3.21MN/A0.00%N/AN/AN/AN/A
MYNZ
MAINZ BIOMED NV
$3.78MN/A0.00%N/AN/AN/AN/A
BDSX
BIODESIX INC
$64.63MN/A0.00%N/AN/AN/AN/A
CHEK
CHECK-CAP LTD
$3.92MN/A0.00%N/AN/AN/AN/A
IMDX
INSIGHT MOLECULAR DIAGNOSTICS INC
$70.98MN/A0.00%N/AN/AN/AN/A
BIAF
BIOAFFINITY TECHNOLOGIES INC
$6.80MN/A0.00%N/AN/AN/AN/A

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Sep 2025?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the #1 top diagnostic & research stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Fonar (NASDAQ:FONR) is: Value: B, Growth: C, Momentum: C, Sentiment: C, Safety: B, Financials: C, and AI: C.

Fonar (NASDAQ:FONR) has a Due Diligence Score of 39, which is 13 points higher than the diagnostic & research industry average of 26.

FONR passed 11 out of 33 due diligence checks and has average fundamentals. Fonar has seen its stock lose -3.82% over the past year, overperforming other diagnostic & research stocks by 14 percentage points.

2. Sotera Health Co (NASDAQ:SHC)


Sotera Health Co (NASDAQ:SHC) is the #2 top diagnostic & research stock out of 56 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Sotera Health Co (NASDAQ:SHC) is: Value: C, Growth: A, Momentum: C, Sentiment: B, Safety: A, Financials: C, and AI: C.

Sotera Health Co (NASDAQ:SHC) has a Due Diligence Score of 24, which is -2 points lower than the diagnostic & research industry average of 26. Although this number is below the industry average, our proven quant model rates SHC as a "A".

SHC passed 8 out of 33 due diligence checks and has weak fundamentals. Sotera Health Co has seen its stock lose -5.22% over the past year, overperforming other diagnostic & research stocks by 12 percentage points.

Sotera Health Co has an average 1 year price target of $14.33, a downside of -8.24% from Sotera Health Co's current stock price of $15.62.

Sotera Health Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Sotera Health Co, 66.67% have issued a Strong Buy rating, 0% have issued a Buy, 33.33% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Idexx Laboratories (NASDAQ:IDXX)


Idexx Laboratories (NASDAQ:IDXX) is the #3 top diagnostic & research stock out of 56 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Idexx Laboratories (NASDAQ:IDXX) is: Value: C, Growth: C, Momentum: B, Sentiment: B, Safety: B, Financials: A, and AI: B.

Idexx Laboratories (NASDAQ:IDXX) has a Due Diligence Score of 50, which is 24 points higher than the diagnostic & research industry average of 26.

IDXX passed 17 out of 33 due diligence checks and has strong fundamentals. Idexx Laboratories has seen its stock return 37.05% over the past year, overperforming other diagnostic & research stocks by 54 percentage points.

Idexx Laboratories has an average 1 year price target of $625.83, a downside of -2.67% from Idexx Laboratories's current stock price of $642.99.

Idexx Laboratories stock has a consensus Buy recommendation according to Wall Street analysts. Of the 6 analysts covering Idexx Laboratories, 33.33% have issued a Strong Buy rating, 16.67% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Quest Diagnostics (NYSE:DGX)


Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.28%, which is 1 percentage points higher than the diagnostic & research industry average of 0.65%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 36.6% indicates that its dividend yield is sustainable for the long-term.

2. Labcorp Holdings (NYSE:LH)


Labcorp Holdings (NYSE:LH) has an annual dividend yield of 1.03%, which is the same as the diagnostic & research industry average of 0.65%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 31.5% indicates that its dividend yield is sustainable for the long-term.

3. Agilent Technologies (NYSE:A)


Agilent Technologies (NYSE:A) has an annual dividend yield of 0.57%, which is the same as the diagnostic & research industry average of 0.65%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 22.9% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks up?

Diagnostic & research stocks were up 1.02% in the last day, and up 0.09% over the last week. Ispecimen was the among the top gainers in the diagnostics & research industry, gaining 27.46% yesterday.

iSpecimen shares are trading higher after the company announced it advanced its $200 million Solana-based digital asset strategy.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Icon (NASDAQ:ICLR)


Icon (NASDAQ:ICLR) is the most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 43, which is 28 points higher than the diagnostic & research industry average of 15. It passed 3 out of 7 valuation due diligence checks.

Icon's stock has dropped -43.22% in the past year. It has underperformed other stocks in the diagnostic & research industry by -26 percentage points.

2. Fonar (NASDAQ:FONR)


Fonar (NASDAQ:FONR) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Fonar has a valuation score of 71, which is 56 points higher than the diagnostic & research industry average of 15. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has dropped -3.82% in the past year. It has overperformed other stocks in the diagnostic & research industry by 14 percentage points.

3. Illumina (NASDAQ:ILMN)


Illumina (NASDAQ:ILMN) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Illumina has a valuation score of 29, which is 14 points higher than the diagnostic & research industry average of 15. It passed 2 out of 7 valuation due diligence checks.

Illumina's stock has dropped -23.76% in the past year. It has underperformed other stocks in the diagnostic & research industry by -6 percentage points.

Are diagnostic & research stocks a good buy now?

55% of diagnostic & research stocks rated by analysts are a buy right now. On average, analysts expect diagnostic & research stocks to rise by 7.08% over the next year.

4.76% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 14.29% of diagnostic & research stocks are rated B (Buy), 61.9% are rated C (Hold), 14.29% are rated D (Sell), and 4.76% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 22x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.